Explain this page
Arphra AIPlain-English read on Biogen Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Peers
- TEVATeva Pharmaceutical Industries Limited$34.95$40.7B
- UTHRUnited Therapeutics Corporation$570.40$25B
- DXCMDexCom, Inc.$61.35$23.67B
- DGXQuest Diagnostics Incorporated$192.67$21.33B
- LHLabcorp Holdings Inc.$255.84$21.06B
- STESTERIS plc$214.40$21.04B
- INCYIncyte Corporation$96.91$19.36B
- WATWaters Corporation$307.12$18.28B
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.77% | -0.81% | +2.93% | +0.37% | +8.30% | +9.40% | +46.82% | -36.33% | -27.93% | -32.87% | +6061.12% |
Aftermarket
LiveLast trade
$192.53
1 sh
Bid
$192.20
10 sh
Ask
$192.75
100 sh
Spread
$0.550
Sector & industry today
LiveSectors
- Technology+4.09%
- Energy+0.86%
- Basic Materials+0.68%
- Industrials+0.09%
- Consumer Cyclical+0.06%
- Communication Services-0.12%
- Utilities-0.33%
- Real Estate-0.52%
- Consumer Defensive-0.84%
- Healthcare-1.06%
- Financial Services-1.11%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-1.52%
- Software - Infrastructure+6.09%
- Computer Hardware+6.02%
- Luxury Goods-4.68%
- Coal+4.38%
- Semiconductors+3.89%
- Medical - Healthcare Information Services+3.43%
- Paper, Lumber & Forest Products-3.35%
- Software - Application+3.30%
- Copper+3.12%
- Consulting Services+3.11%
- Agricultural Farm Products+2.95%
Fair value
Football field →Weighted blend
$703.58
+265.43% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
11bull3bear
±5% threshold
Analyst PT consensus: $211.42 (+9.81%)
Total assets
$29.44B
Total debt
$6.95B
Cash & equiv
$3.01B
Operating CF
$2.2B
Free cash flow
$2.05B
Buybacks
$0
Analyst view
DB · price_targets + analyst_gradesConsensus target
$211.42
+9.81% upside
Low
$143.00
Median
$214.00
High
$260.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Diseaseprnewswire.com·May 08, 2026
- Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Diseaseprnewswire.com·May 08, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $2.48B | $319.5M | $2.15 |
| Q4 Dec 2025 | $2.28B | -$48.41M | $-0.33 |
| Q3 Sep 2025 | $2.45B | $466.5M | $3.17 |
| Q2 Jun 2025 | $2.65B | $634.8M | $4.35 |
| Q1 Mar 2025 | $2.43B | $240.5M | $1.64 |
| Q4 Dec 2024 | $2.45B | $266.7M | $1.83 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Murphy Nicole officer: Head of Pharm Ops and Tech | Buy | 3 | $585.11 | Feb 12, 2026 |
Singhal Priya officer: Head of Development | Sell | 2,660 | $531.55K | Feb 09, 2026 |
Singhal Priya officer: Head of Development | Sell | 748 | $134.12K | Feb 02, 2026 |
Singhal Priya officer: Head of Development | Sell | 517 | $69.05K | Sep 02, 2025 |
Izzar Rachid officer: Head of Global Product Strat. | Sell | 2,223 | $300.11K | Jul 08, 2025 |
Singhal Priya officer: Head of Development | Sell | 3,806 | $480.51K | May 19, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $9.81B | $1.88B | $1.29B | $8.83 | +13.18% |
| FY 2024 | $9.68B | $2.49B | $1.63B | $11.19 | +16.87% |
| FY 2023 | $9.84B | $2.1B | $1.16B | $7.97 | +11.81% |
| FY 2022 | $10.17B | $2.89B | $3.05B | $20.87 | +29.95% |
| FY 2021 | $10.98B | $2.79B | $1.56B | $10.40 | +14.17% |